Paricalcitol

Paricalcitol is a lipid of Sterol Lipids (ST) class. Paricalcitol is associated with abnormalities such as Vitamin D Deficiency. The involved functions are known as Hypertrophy, Left Ventricular. Paricalcitol often locates in Blood.

Cross Reference

Introduction

To understand associated biological information of Paricalcitol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Paricalcitol?

Paricalcitol is suspected in Vitamin D Deficiency and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

No disease MeSH terms mapped to the current reference collection.

PubChem Associated disorders and diseases

What pathways are associated with Paricalcitol

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Paricalcitol?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Paricalcitol?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Paricalcitol?

There are no associated biomedical information in the current reference collection.

What genes are associated with Paricalcitol?

There are no associated biomedical information in the current reference collection.

What common seen animal models are associated with Paricalcitol?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Paricalcitol

Download all related citations
Per page 10 20 50 100 | Total 375
Authors Title Published Journal PubMed Link
Eren Z et al. Effects of paricalcitol and aliskiren combination therapy on experimental diabetic nephropathy model in rats. 2014 Kidney Blood Press. Res. pmid:25532067
Lee JW et al. Renoprotective effect of paricalcitol via a modulation of the TLR4-NF-κB pathway in ischemia/reperfusion-induced acute kidney injury. 2014 Biochem. Biophys. Res. Commun. pmid:24434153
Pauwels S et al. Minimal interference from paricalcitol (Zemplar®) in underivatized 1,25-dihydroxyvitamin D LC-MS/MS assays. 2014 Clin. Chim. Acta pmid:24326126
Guo C et al. Synergistic induction of human cathelicidin antimicrobial peptide gene expression by vitamin D and stilbenoids. 2014 Mol Nutr Food Res pmid:24039193
Azak A et al. Effect of novel vitamin D receptor activator paricalcitol on renal ischaemia/reperfusion injury in rats. 2013 Ann R Coll Surg Engl pmid:24112495
Chen B et al. Synthesis of VS-105: A novel and potent vitamin D receptor agonist with reduced hypercalcemic effects. 2013 Bioorg. Med. Chem. Lett. pmid:24035340
Bae S et al. Vitamin D signaling pathway plays an important role in the development of heart failure after myocardial infarction. 2013 J. Appl. Physiol. pmid:23429874
Duplancic D et al. The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection. 2013 Clin Interv Aging pmid:23430986
Piñera-Haces C et al. Double treatment with paricalcitol-associated calcifediol and cardiovascular risk biomarkers in haemodialysis. 2013 Nefrologia pmid:23364629
Han T et al. Meta-analysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease. 2013 Biomed Res Int pmid:23509710